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Homocysteine activates NADH/NADPH oxidase through
ceramide-stimulated Rac GTPase activity in rat mesangial cells.
Background. We recently demonstrated that homocys-
teine (Hcys) increases superoxide (O2−) production via
NADH/NADPH oxidase in renal mesangial cells. This O2−
production contributes to increased expression of tissue
inhibitor of metalloproteinase (TIMP-1) and consequent de-
position of collagen in response to Hcys. However, the mecha-
nism by which Hcys activates NADH/NADPH oxidase remains
unknown. Given that ceramide is an intracellular activator of
this oxidase in several cell types, the present study tests the hy-
pothesis that Hcys activates NADH/NADPH oxidase through
a ceramide-mediated signaling pathway in rat mesangial (MG)
cells, resulting in O2− production.
Methods. Rat MG cells were incubated with L-homocysteine
(L-Hcys) to determine the mechanism by which Hcys activates
NADH/NADPH oxidase. Thin layer chromatography (TLC),
Western blot analysis, Rac GTPase activity pull down assay,
and NADH/NADPH oxidase activity measurements were per-
formed.
Results. TLC analysis demonstrated that L-Hcys increased
de novo production of ceramide in MG cells. L-Hcys and in-
creased ceramide did not alter the amount of NADH/NADPH
oxidase subunit p47phox and p67phox in both membrane and cy-
tosolic fractions from MG cells. However, L-Hcys or ceramide
markedly increased the level of GTP-bound Rac, which was ac-
companied by enhanced activity of NADH/NADPH oxidase.
These Hcys or ceramide-induced actions were substantially
blocked by a Rac GTPase inhibitor, GDPbS, and a de novo
ceramide synthesis inhibitor, fumonisin B1 (FB1).
Conclusion. These results indicate that Hcys activates
NADH/NADPH oxidase by stimulating de novo ceramide syn-
thesis, and subsequently enhancing Rac GTPase activity in rat
MG cells. This ceramide-Rac GTPase signaling pathway may
mediate Hcys-induced oxidative stress in these glomerular cells.
Homocysteine (Hcys) is a sulfur-containing amino acid
formed during the metabolism of methionine. Hyperho-
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mocysteinemia has been found in many patients with dif-
ferent cardiovascular diseases, especially in those patients
with premature atherosclerosis of coronary, carotid, and
peripheral arteries. Elevated plasma Hcys levels have
been implicated as an independent risk factor for arte-
riosclerosis and coronary heart disease [1–2]. In previ-
ous experimental studies, Hcys was shown to produce
endothelial dysfunction and stimulate the proliferation
of vascular smooth muscle cells and other cells. It also
increased the formation of extracellular matrix (ECM),
which may activate or promote the sclerotic process in
vessel walls and other tissues [3–5]. Recent reports in
our laboratory have indicated that chronic elevations of
plasma Hcys induce glomerulosclerosis with mesangial
expansion, and that increased Hcys levels play an im-
portant role in the development of glomerulosclerosis
associated with hypertension in the Dahl salt-sensitive
rat model. Further studies have demonstrated that Hcys
increases the O2− production via NADH/NADPH ox-
idase and, therefore, stimulates the formation of tissue
inhibitor of metalloproteinase-1 (TIMP-1) in renal
mesangial cells, consequently producing the deposition
of collagen in response to Hcys [6]. However, the mech-
anism by which Hcys activates NADH/NADPH oxidase
remains unknown.
NADH/NADPH oxidase is a membrane-associated
enzyme that uses electrons derived from intracellular
NADH or NADPH to generate O2−. Since both NADH
and NADPH are the substrates for this enzyme, it is usu-
ally named as NADH/NADPH oxidase, or NAD(P)H ox-
idase. Generally, the NADH/NADPH oxidase system is
composed of multiple membrane-associated and cytoso-
lic components, including gp91phox, p22phox (membrane-
associated), p40phox, p47phox, p67phox, and Rac (cytosolic).
Recently, different NADH/NADPH oxidase subunits
have been identified in the kidney and are thought to
be an important source of O2− in the kidney [1, 3, 7].
Studies in our laboratory and by others have demon-
strated that this enzyme plays an important role in me-
diating O2− production in the kidney, especially in the
glomeruli and thick ascending loop of Henle (TALH) [6,
8]. NADH/NADPH oxidase-mediated O2− production
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has been implicated in the regulation of renal function un-
der physiologic and pathologic conditions. Our findings
that Hcys activates NADH/NADPH oxidase in MG cells
strongly suggest that oxidative stress mediated by this en-
zyme may be importantly involved in the development of
end-stage renal diseases associated with hyperhomocys-
teinemia. Therefore, it is imperative to clarify how Hcys
activates this enzyme.
Because ceramide, a sphingolipid, has been reported as
one of critical signaling molecules to mediate the activa-
tion of NADH/NADPH oxidase in different cells, and this
enzyme contains a regulatory component, Rac protein,
which processes a high affinity to lipid binding [9], the
present study examined whether ceramide signaling con-
tributes to Hcys-induced activation of NADH/NADPH
oxidase in rat MG cells. Then, we went on to explore the
mechanism by which ceramide production mediates the
effects of Hcys on the activity of NADH/NADPH oxi-
dase. Given the possible involvement of subunit p47phox
translocation and Rac GTPase in the regulation of this
enzyme, we examined the action of L-Hcys or ceramide
on these two activating processes of NADH/NADPH oxi-
dase in rat MG cells. Our results provide evidence indicat-
ing that Hcys stimulates the de novo synthesis of ceramide
and consequently activates Rac GTPase, thereby result-
ing in O2− production via enhanced NADH/NADPH ox-
idase activity.
METHODS
Culture of rat MG cells
Rat MG cells were obtained from the American Type
Culture Collection (ATCC) and incubated and propa-
gated in Dulbecco’s modified Eagle’s medium (DMEM)
containing 18 mmol/L sodium bicarbonate, 25 mmol/L
glucose, 0.6 lmol/L G418, and 15% fetal bovine serum
(FBS) with 4 mmol/L L-glutamine at 37◦C in 5% CO2
atmosphere as we described previously [10, 11]. The cells
were used when they reached 70% to 90% confluence.
Between the D- and L-forms of Hcys, L-Hcys produces
pathogenic effects; therefore, we treated rat MG cells
with L-Hcys at concentrations of 20 to 80 lmol/L. In
the present study, the concentration and the incubation
time of L-Hcys treatment were chosen based on pre-
vious studies [6] and our preliminary experiments. It
was found that L-Hcys (20–80 lmol/L) induced a time-
and concentration-dependent increase O2− production
in rat MG cells, which was significantly attenuated by the
NAD(P)H oxidase inhibitor diphenylene iodonium chlo-
ride (DPI) (data not shown). Therefore, in the present
study, we treated rat MG cells with L-Hcys (80 lmol/L)
for 16 hours to obtain the maximal effect of L-Hcys treat-
ment. Because L-Hcys is not commercially available, it
was prepared from L-Hcys thiolactone as described pre-
viously [12]. Briefly, L-Hcys thiolactone was dissolved in
water, hydrolyzed with KOH for 12 minutes at 45◦C to
remove the thiolactone group, then neutralized with HCl
and cooled to 0◦C with constant nitrogen purging. Freshly
prepared L-Hcys was used in all experiments.
Ceramide assay
Endogenous ceramide production in rat MG cells
was determined by diacetylglycerol (DAG) kinase as-
say as we reported previously [13, 14]. In brief, conflu-
ent rat MG cells were quickly frozen in liquid N2, and
homogenized in 4 volumes of 10 mmol/L phosphate-
buffered saline (PBS). An aliquot of homogenate was
used to measure protein concentration. The supernatant
was transferred to a 15 mL glass tube, and sufficient
1 mol/L NaCl was added to bring the aqueous volume
to 0.8 mL. Samples were then extracted with 3 mL of
chloroform/methanol (1:2, v/v), with a final chloroform-
methanol-water (1:2:0.8, v/v). Samples were then soni-
cated three to four times to facilitate lipid extraction.
After incubation at room temperature for three hours,
samples were centrifuged at 3000g for 5 minutes, and
the supernatant was transferred to another tube. Then,
1 mL chloroform and 1 mL 1 mol/L NaCl were added
to make a chloroform-methanol-NaCl ratio of 2:1:1.8. To
break the phases, samples were vortexed and centrifuged
at 3000 rpm for 5 minutes. The lower layer (organic layer)
was dried under N2 and used for the analysis of ceramide
within 72 hours.
An aliquot of dried lipid was solubilized by bath
sonication into a detergent solution [7.5% n-octyl-b-D-
glucopyranoside, 5 mmol/L cardiolipin in 1 mmol/L di-
ethylenetriaminepentaacetic acid (DTPA)] and mixed
with bacterial DAG kinase (Calbiochem, CA, USA) and
4 lCi [b-32P]-ATP to a final volume of 100 lL. After incu-
bation at 25◦C for 3 hours, the reaction was stopped by ex-
traction of lipids with 600 lL chloroform:methanol (1:1,
v/v), 20 lL 1% perchloric acid, and 150 lL 1 mol/L NaCl.
Then, the lower organic phase was recovered, washed
twice with 1% perchloric acid, and dried with N2. The
32P-labeled ceramide was separated from other lipids by
thin layer chromatography (TLC) with a solvent con-
sisting of chloroform:acetone:methanol:acetic acid:water
(10:4:3:2:1, v/v/v/v/v). After autoradiographic visualiza-
tion by exposure to x-ray film, the ceramide 1-32P band
was recovered by scraping and counted in a Beckman
model liquid scintillation counter (Beckman Coulter,
Fullerton, CA, USA). The amount of ceramide in lipid
extracts was calculated from a standard curve constructed
with known amounts of C6-ceramide (Sigma, St. Louis,
MO, USA), and expressed as nmol/mg protein.
Sphingomyelinase assay
Sphingomyelinase (SMase) is one of the enzyme
systems responsible for ceramide production, which
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metabolizes sphingomyelin into ceramide and choline.
The activity of sphingomyelinase was determined us-
ing radiospectrometry [15, 16]. Briefly, [N-methyl 14C]-
sphingomyelin was incubated with MG cell homogenates,
then the metabolites of sphingomyelin, 14C-choline phos-
phate and ceramide, were quantitated. For magnesium-
dependent neutral SMase (N-SMase), an aliquot of the
homogenates (20 lg protein) was incubated with a neu-
tral reaction buffer containing 100 mmol/L Tris-HCl (pH
7.5), 5 mmol/L MgCl2, and 0.05% Triton X-100, and
mixed with 0.1 mmol/L [N-methyl 14C]-sphingomyelin
(0.02 lCi) in a final volume of 100 lL. After incubation at
37◦C for 15 minutes, the reaction was stopped by adding
1.5 mL of chloroform/methanol (2:1, v/v), followed by ad-
dition of 0.2 mL of H2O. The samples were then vortexed
and centrifuged at 3000 rpm for 5 minutes to separate
the two phases. A portion of the upper aqueous phase
was transferred to scintillation vials and counted for the
formation of 14C-choline phosphate in a Beckman liquid
scintillation counter. Acidic SMase (A-SMase) activity
was determined using an acidic reaction buffer containing
100 mmol/L sodium acetate (pH 5.0), 0.05% Triton X-100,
and 0.1 mmol/L [N-methyl 14C]-sphingomyelin (0.02 lCi)
in a final volume of 100 lL. The 14C-choline phosphate
formation rate was calculated to represent the enzyme
activity.
To confirm the accumulation of ceramide in the reac-
tion mixtures, thin layer chromatography (TLC) was per-
formed in some experiments. Briefly, the lower organic
phase after lipid extraction was collected and separated
sequentially on a silica gel TLC LK6D plate (Whatman
International, Ltd., Maidstone, England) with two sol-
vent systems (chloroform/methanol/25% ammonium
hydroxide/water 50:50:2:1 and 90:10:0.5:0.5, v/v/v/v).
Sphingomyelin and ceramide were visualized by iodine
staining, and comparison made with synthetic sphin-
gomyelin and ceramide standards.
Western blot analysis
The homogenates, cytosol, or membrane of rat MG
cells were prepared as we reported previously [17, 18].
Western blot analysis was performed to determine the
relative quantities of NADH/NADPH oxdiase subunit
p47phox, p67phox, and gp91phox in these cell fractions.
Briefly, cell homogenates, cytosol or membrane (20 lg)
were loaded and separated by a 12% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE). The proteins of these samples were then
electrophoretically transferred at 100 V for 1 hour onto
a nitrocellulose membrane. The membrane was blocked
with 5% nonfat dry milk in Tris-buffered saline-Tween
20, and probed at room temperature with a monoclonal
antibody against p47phox, p67phox, and gp91phox (1:500
dilution for 2 hours, BD Transduction Laboratories,
Lexington, KY, USA). After washing, the membrane
was incubated for 1 hour with a horseradish peroxidase–
conjugated rabbit antimouse IgG (Amersham Pharmacia
Biotech, Piscataway, NJ, USA) at a dilution of 1:5000
for monoclonal primary antibodies, then washed and
incubated for 1 minute with SuperSignal West Pico
detection reagents (Pierce, Rockford, IL, USA). To
make gel documentation, the membrane was wrapped
in Saran Wrap, and then exposed to Fuji medical x-ray
film (Fuji, Tokyo, Japan).
To document the loading controls, the membrane was
reprobed with a primary antibody against housekeep-
ing protein, b-actin, after the membrane was stripped by
incubating at 50◦C for 30 minutes in a buffer contain-
ing Tris-HCl (67.5 mmol/L, pH 6.8), b-mercaptoethanol
(100 mmol/L), and SDS (2%). After washing, the
membrane was incubated in 5% nonfat dry milk in
Tris-buffered saline-Tween 20, and subsequently with a
monoclonal antibody against b-actin (1:4000 dilution for
2 hours; Sigma) and then a secondary antibody. The
membrane was washed, and the immunoreactive band
of b-actin visualized by reaction with detection solu-
tion as described above. All films with immunoreactive
blots were scanned by a densitometer and the intensity
of corresponding protein bands was quantitated using
UN-SCAN-IT software (Silk Scientific, Inc., Orem, UT,
USA).
Rac GTPase activation assays
Rac GTPase is a small G protein that is reported to reg-
ulate NADH/NDAPH oxidase activity in different cells.
To determine its involvement in the action of Hcys or ce-
ramide, a specific pull-down experiment was performed,
and Rac GTPase activation was measured using a Rac
activation assay kit (Upstate, Lake Placid, NY, USA).
Briefly, after stimulation with L-Hcys and C2-ceramide,
rat MG cells were lysed in Mg2+ lysis buffer (MLB).
The cell lysate was precleaned by adding 100 lL of glu-
tathione agarose per 1 mL, and then incubating with
continuous agitation for 10 minutes at 4◦C. Then, the
agarose beads were collected by a 5-second spin in a mi-
crocentrifuge at 14,000g. The supernatant was collected
and stored in aliquots on ice, and protein concentrations
were determined by BCA assay kit (Bio-Rad, Hercules,
CA, USA). Each cell extract with 600 lg protein was
aliquoted into three microfuge tubes and used for Rac
GTPase activity assay. GTPcS was used as a positive con-
trol for in vitro stimulation of Rac GTPase, while GDP
was used to determine basal GTPase activity without
stimulations. The control experiments were performed
by using 2 lL of 0.5 mol/L EDTA (substituted for pull-
down proteins), 2 lL of 100× GTPcS and GDP. Tubes
were incubated at 30◦C for 15 minutes with agitation, and
the reactions were terminated by placing the tubes on ice
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and adding 65 lL of 1 mol/L MgCl2. The pull-down pro-
teins (200 lg per sample), together with positive controls,
were incubated with 8 lg of PAK-1 PBD [Glutathione-S-
Transferase fusion protein, corresponding to p21-binding
domain (PBD, residues of 67–150) of human protein ac-
tivating kinase-1 (PAK-1)] agarose for one hour at 4◦C to
bind Rac-GTP in the samples. Then, the supernatant was
removed and discarded. The pelleted beads were washed
three times with 0.5 mL of MLB, resuspended in 25 lL
of 2× Laemmli reducing sample buffer, and boiled for 5
minutes. The sample mixtures were then loaded on 12%
SDS-PAGE gels. The bound active GTP-Rac molecules
in the beads and total Rac in the cell lysates were analyzed
by Western blot using an anti-Rac monoclonal antibody.
Measurements of basal O2− levels and NADH/NADPH
oxidase activity in rat MG cells
Fluorescence spectrometry for O2− production in rat
MG cells was performed by using a modification of meth-
ods described previously [19, 20]. Briefly, the fluorogenic
oxidation of dihydroethidium (DHE) to ethidium (Eth)
was used as a measure of O2−. The homogenates (10
lg) freshly prepared from rat MG cells were incubated
with DHE (10 lmol/L) and salmon testes DNA (0.5
mg/mL) with or without NADH (2 mmol/L) in a mi-
crotiter plate at 37◦C for 30 minutes, and then Eth-DNA
fluorescence was measured at an excitation of 475 nm
and an emission of 610 nm by using a CytoFluor Series
4000-fluorescence microplate reader (Applied Biosys-
tems, Foster City, CA, USA). The Eth fluorescence in the
cells incubated without NADH was quantitated as basal
O2− levels in these cells. NADH/NADPH oxidase activ-
ity to produce O2− in MG cells was examined by addi-
tion of NADH (0.1 mmol/L) as a substrate in the reaction
mixture. Salmon DNA was added to bind to Eth and con-
sequently stabilize Eth fluorescence, thereby increasing
the sensitivity of O2− measurement (>40-fold). The en-
zyme activity of NADH/NADPH oxidase and O2− levels
were presented as percent increases in Eth fluorescence
versus control. These DHE fluorescent spectrometric as-
says of basal O2− levels and NADH oxidase activity were
described in our previous studies [8, 21].
Statistical analysis
Data are presented as mean ± SEM. Significance of
difference in mean values within and between multi-
ple groups was examined with an analysis of variance
(ANOVA) for repeated measures followed by a Dun-
can’s post hoc test. Student t test was used to evaluate
the significance of differences between two groups of ex-
periments (SigmaStat; SPSS, Inc., Chicago, IL, USA). A
value of P < 0.05 was considered statistically significant.
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Fig. 1. Effect of L-homocysteine (L-Hcys) on ceramide (Cer) concen-
trations in rat mesangial (MG) cells. Representative autoradiograph
of phospholipids fractionated by thin-layer chromatography (TLC)
after DG kinase assay (A). The bands shown represent ceramide-1-
phosphate (Cer-1-P), which are from endogenous ceramide, and C6:0
ceramide-1-phosphate (C6-Cer-1-P) from internal standard, respec-
tively. Summarized quantitative changes in ceramide-1-phosphate (B).
The Cer-1-P and C6-Cer-1-P bands were scraped, and the radioactivity
was counted using a liquid scintillation counter. Values are mean ± SE
from five separate experiments. ∗P < 0.05 vs. control.
RESULTS
Effects of L-Hcys on ceramide production in rat MG cells
To provide direct evidence that L-Hcys stimulates pro-
duction of ceramide, a DAG kinase assay was performed
in rat MG cells treated with vehicle or L-Hcys (20, 40,
or 80 lmol/L) for 16 hours. A representative TLC au-
toradiograph is presented in Figure 1A. In agreement
with our previous reports [13, 22], two major radiola-
beled phospholipid bands were detected in the extracts
of rat MG cells, including phosphorylated endogenous
ceramides and dihydroceramides (Cer-1-P), which comi-
grated with type III ceramide-1-phosphate and a phos-
phorylated C6:0 ceramide internal standard (C6Cer-1-
P), respectively. By determining the radioactivity of
scrapped Cer-1-P bands, we found that basal ceramide
levels were detectable in control rat MG cells. L-Hcys
treatment of these cells produced a significant increase
in ceramide levels. As summarized in Figure 1B, the
basal ceramide concentration in rat MG cells was 1.53 ±
0.059 nmol/mg protein, and L-Hcys concentration depen-
dently increased ceramide levels in these cells, with a 47%
increase at a concentration of 80 lmol/L.
Effects of L-Hcys on SMase activity
To determine whether Hcys stimulates ceramide pro-
duction through activation of SMases in rat MG cells,
we measured the activity of both A-SMase and N-SMase
in rat MG cells before and after treatment with L-Hcys.
As shown in Figure 2, the activity of A-SMase averaged
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Fig. 2. Effect of L-Hcys on the activity of sphingomyelinases (SMases)
activity in rat MG cells. A-SMase and N-SMase represent acidic and
neutral SMases, respectively. Values are mean ± SE from five separate
experiments.
0.02 ± 0.0018 nmol/min per mg protein, which was signif-
icantly greater than 0.007 nmol/min per mg protein of N-
SMase activity. However, neither N-SMase nor A-SMase
activity was altered in rat MG cells treated with L-Hcys.
These results suggest that increased ceramide production
by L-Hcys is not through SMase-mediated catabolism of
sphingomyeline, but rather through other mechanisms.
Enhanced de novo ceramide synthesis in L-Hcys–treated
MG cells
Recent studies have reported that ceramide can be
also synthesized rapidly in response to different stimuli.
We wondered whether Hcys-stimulated ceramide pro-
duction is associated with activation of this de novo
ceramide synthesis. To answer this question, a selective
inhibitor of de novo ceramide synthesis, FB1, was used
to examine whether Hcys-increased ceramide production
could be blocked. FB1 blocks ceramide synthase activ-
ity, and thereby, reduces ceramide production [23, 24]. It
was found that FB1 (0.1–10 lmol/L) significantly blocked
L-Hcys–induced increase in ceramide levels in rat MG
cells in a concentration-dependent manner. The effect of
L-Hcys increasing ceramide production was completely
blocked at 1 lmol/L FB1. At a high concentration of FB1
(10 lmol/L), ceramide decreased to a level even lower
than basal level of ceramide in these MG cells (Fig. 3).
No effect of L-Hcys or ceramide on NADH/NADPH
oxidase expression level and subunits translocation
in rat MG cells
First, we examined the effect of L-Hcys or ceramide
on the expression level of NADH/NADPH oxidase sub-
units in cultured rat MG cells. After treatment of rat
MG cells with L-Hcys (80 lmol/L) for 16 hours or a cell
permeable C2-ceramide (15 lmol/L) for 45 minutes, the
homogenates of these cells were prepared. The subunits
p47phox, p67phox, and gp91phox of NADH/NADPH oxi-
dase were detected by Western blot analysis. As shown
2.5
2.0
1.5
1.0
0.5
0.0C
er
am
id
e 
co
nc
en
tra
tio
n,
n
m
ol
/m
g 
pr
ot
.
C 0 0.1 1 10 FB1 (µmol/L)
Hcys (80 µmol/L)
*
#
#
Fig. 3. Effect of de novo ceramide synthesis inhibitor fumonisin B1
(FB1) on ceramide levels in L-Hcys–treated rat MG cells. Values are
mean ± SE from four separate experiments. ∗P < 0.05 vs. control;
#P < 0.05 vs. vehicle of FB1 treatment.
in Figure 4A, the amount of these subunits in rat MG
cells had no significant change before and after incuba-
tion of the cells with L-Hcys. The results are summarized
in Figure 4B. In our previous studies in endothelial cells,
the translocation of p47phox was found to primarily me-
diate activation of NADH/NADPH oxidase in response
to tumor necrosis factor-a (TNF-a). This p47phox translo-
cation has also been demonstrated to be an activating
mechanism of NADH/NADPH oxidase in other cells
[18, 25, 26]. To determine the mechanism by which Hcys
or ceramide activates NADH/NADPH oxidase, we then
examined the effects of L-Hcys or C2-ceramide on the
translocation of oxidase subunits from cytosol to the cell
membrane. As shown in Figure 4C, the amount of p47phox
in cell membrane and cytosol were similar before and af-
ter incubation of the cells with L-Hcys. Previous studies
showed that the translocation of subunit p67phox from the
cytosol to the membrane is essential for NADH/NADPH
oxidase activity. p67phox contains two SH3 domains and
binds, via its C-terminal SH3, to the praline-rich region
of p47phox. This binding allows p67phox to directly asso-
ciate with p47phox for the activity of NADH/NADPH ox-
idase. Consistent with the effect of L-Hcys on p47phox, the
amount of p67phox in cell membrane and cytosol fractions
was not altered by L-Hcys treatment. These results were
summarized in Figure 4D. Similarly, C2-ceramide had no
effect on p47phox and p67phox levels in either cytosol or
cell membrane (data not shown).
Activation of Rac GTPase by L-Hcys and ceramide
in rat MG cells
As stated above, Rac is a regulatory element that plays
an important factor in the activation of NADH/NADPH
oxidase. Given that translocation of p47phox subunit
seems not to be involved in the action of L-Hcys–
or ceramide-induced activation of NADH/NADPH oxi-
dase, we examined whether Hcys stimulates Rac GTPase
activity through ceramide, resulting in activation of this
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Fig. 4. Effects of L-Hcys on NADH/NADPH oxidase expression level
and the translocation of subunits in rat MG cells. Immunoblot for
p47phox, p67phox, and gp91phox in the homogenates of rat MG cells
with and without treatment of L-Hcys (A). Summarized data showing
changes in p47phox, p67phox, and gp91phox in rat MG cells (N = 5) (B).
Immunoblot for p47phox, p67phox in both cell membrane and cytosol of
rat MG cells with and without treatment of L-Hcys (C). Summarized
data showing changes in p47phox, p67phox in both cell membrane and
cytosol of rat MG cells (N = 5) (D).
enzyme in rat MG cells. As documented in Figure 5A, L-
Hcys produced a significant increase in GTP-bound Rac
protein levels in control or GDP-treated MG cells. When
the cells were pretreated with a stable G-protein activa-
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Fig. 5. Effect of L-Hcys on Rac GTPase activity in rat MG cells. Im-
munoblot for Rac GTPase activity in rat MG cells (A). GTPcS was
used as a positive control for in vitro stimulation of Rac GTPase, while
GDP was used to determine basal GTPase activity without stimulations.
Summarized data showing changes in Rac GTPase activity in rat MG
cells (N = 4) (B). ∗P < 0.05 vs. control, #P < 0.05 vs. vehicle of GDP
treatment.
tor, GTPcS, GTP-bound Rac protein levels increased sig-
nificantly. In the presence of GTPcS, L-Hcys did not have
further effect on GTP-bound Rac levels. The results from
these experiments are summarized in Figure 5B. L-Hcys
increased GTP-bound or activated Rac levels by 37.6%
and 56.4% in vehicle and GDP-treated MG cells, respec-
tively. In the cells treated with GTPcS, a 1.8-fold increase
in activated Rac level was observed, regardless of the ab-
sence or presence of L-Hcys treatment. However, total
Rac levels, including GTP-bound and GDP-bound Rac,
were not significantly altered by L-Hcys. Densitometric
analysis demonstrated no difference in total Rac levels
from vehicle-treated (C) and L-Hcys–treated MG cells
(Fig. 6).
In rat MG cells treated with C2-ceramide (15 lmol/L
for 45 minutes), GTP-bound Rac levels were also sig-
nificantly increased. As documented in Figure 7A, like
L-Hcys, C2-ceramide increased the level of GTP-bound
Rac in MG cells under different conditions. Summarized
data in Figure 7B show that C2-ceramide significantly in-
creased activated Rac levels. If the cells were pretreated
with GTPcS, however, the activated Rac amount maxi-
mally increased what was not decreased or enhanced by
C2-ceramide treatment. Similar to L-Hcys, C2-ceramide
did not alter the level of total Rac in MG cells under any
conditions (data not shown).
To further examine whether Hcys-stimulated activa-
tion of Rac is associated with enhanced production of
ceramide in rat MG cells, we examined the effects of
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Fig. 6. Effect of L-Hcys on the expression levels of total Rac in rat MG
cells. Immunoblot for total Rac expression levels in rat MG cells (A).
Summarized data showing changes in Rac expression in rat MG cells
(N = 4) (B).
inhibition of de novo ceramide synthesis on the in-
crease in Rac activity induced by L-Hcys. As shown in
Figure 8A, L-Hcys significantly increased GTP-bound
Rac levels, but it had no effect on total Rac level in the
presence or absence of FB1, an inhibitor of de novo ce-
ramide synthesis. However, in the presence of FB1, L-
Hcys–induced increase in this activated Rac was substan-
tially reduced. The results are summarized in Figure 8B,
and suggest that FB1 significantly blocked the L-Hycs–
induced increase in activated Rac levels in these cells.
Blockade of L-Hcys–enhanced NADH/NADPH oxidase
activity by inhibition of Rac activity and de novo ceramide
synthesis in rat MG cells
Using fluorescence spectrometric assay, the activity
of NADH/NADPH oxidase was determined in rat MG
cells treated with L-Hcys in the absence or presence of
Rac inhibitor, GDPbS, or de novo ceramide synthesis
inhibitor, FB1. It was found that L-Hcys significantly in-
creased the basal O2− levels and NADH-specific activ-
ity in the homogenates of rat MG cells. As shown in
Figure 9, summarized data demonstrate a significant in-
crease in NADH/NADPH oxidase activity by L-Hcys. In
the presence of GDPbS or FB1, L-Hcys–induced increase
in NADH/NADPH oxidase activity was blocked com-
pletely. Both GDPbS and FB1 even decreased NADH
specific Eth fluorescence to a level lower than control.
DISCUSSION
Recent studies in our laboratory have indicated that
L-Hcys significantly increases NADH/NADPH oxidase
activity, and thereby stimulates O2− production in rat
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Fig. 7. Effect of ceramide (Cer) on Rac GTPase activity in rat MG cells.
Immunoblot for Rac GTPase activity in rat MG cells (A). GTPcS was
used as a positive control for in vitro stimulation of Rac GTPase, while
GDP was used to determine basal GTPase activity without stimulations.
Summarized data showing changes in Rac GTPase activity in rat MG
cells (N = 4) (B). ∗P < 0.05 vs. control, #P < 0.05 vs. vehicle of GDP
treatment.
MG cells, resulting in the abnormal metabolism of ex-
tracellular matrix and consequent glomerular sclerosis.
In the present study, we performed a series of experi-
ments to explore the mechanism by which Hcys enhances
NADH/NDAPH oxidase activity in these MG cells. First,
we determined whether Hcys stimulates the production
of ceramide, a novel lipid second messenger. This lipid-
signaling molecule has been reported to mediate the ac-
tions of various stimuli, such as cytokines, chemotherapy
drugs, and radiation, in a variety of mammalian tissues or
cells. In addition, this signaling lipid has been implicated
in the detrimental actions of many different injury fac-
tors, such as cell death factors [27–30]. Recent studies in
our group have demonstrated that ceramide increased in
ischemic reperfused myocardium and in endothelial cells
exposed to death factors, such as TNF-a, interleukin 2
(IL-2), and endostatin [10, 14, 18]. In these studies, the
ceramide signaling pathway has been confirmed to be
involved in the activation of NADH/NADPH oxidase
and consequent O2− production, thereby leading to de-
creased NO bioavailability and endothelial dysfunction
[31]. Therefore, we hypothesized that the ceramide sig-
naling pathway may also contribute to the action of L-
Hcys on NADH/NADPH oxidase activity in gloermular
mesangial cells, and thereby mediate the action of Hcys
in glomerular injury. To test this hypothesis, we incu-
bated rat MG cells with L-Hcys for 16 hours, and then
quantified cellular ceramide levels using DAG kinase/
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TLC assay. It was found that L-Hcys significantly
increased ceramide concentrations in these rat MG
cells. This result provides direct evidence that indi-
cated that the ceramide signaling pathway may be
involved in the action of Hcys-induced pathologic
change in MG cells. In previous studies, ceramide was
found to be importantly involved in renal glomeru-
lar and tubular pathology [32–34]. Ceramide can trig-
ger apoptosis through a variety of intracellular targets:
ceramide-activated protein kinase (CAPK), MAP ki-
nases, caspases, and transcription factors, such as NF-
jB. Activation of MAP kinases and caspases occurs
during ischemia/reperfusion injury to kidneys [35]. The
potential relevance of ceramide to renal injury has also
been suggested by the facts that TNF-a, a stimulator of
ceramide, induces apoptosis in renal tubule cells, and the
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Fig. 9. Effect of L-Hcys on nicotinamide adenine dinucleotide
(NADH) oxidase activity and O2− production in the presence or ab-
sence of inhibitors GDPbS or FB1 in rat MG cells. Summarized data
showing the effect on L-Hcys and inhibitors on NADH-dependent ac-
tivity in these mesangial cells. Data were presented as percent increases
in ethidium flurescence compared to control (N = 4). ∗P < 0.05 vs.
control, #P < 0.05 vs. vehicle of L-Hcys treatment.
increase in TNF-a can be observed in several models of
acute renal failure [36]. The present study further con-
firms this possible pathologic relevance of ceramide in
the end-stage renal diseases.
To explore the mechanism by which L-Hcys increases
intracellular ceramide levels in rat MG cells, we ex-
amined the involvement of different enzymatic path-
ways in L-Hcys–induced ceramide production. Previous
studies have demonstrated that two major important
biochemical pathways are responsible for ceramide pro-
duction, one of which is via sphingomylinases (SMases).
The Smases are the most extensively studied enzymes
in ceramide metabolism. With the primary focus upon
two major SMases, N-Smase and A-Smase, we first deter-
mined whether SMases are involved in the action of Hcys.
By radiospectrometric assay, we found that L-Hcys–
induced ceramide production was not associated with the
activation of two major Smases, including N-SMase and
A-SMase. Considering that cellular ceramide concentra-
tions are dynamically maintained, SMases should be in-
creased at the same time point that ceramide increases,
if these enzymes involved. Therefore, failure to detect
increased SMase activity suggests that L-Hcys does not
alter the turnover of sphingomyelin in these MG cells
through the SMase pathway.
Another important pathway to synthesize ceramide is
its de novo synthesis. Previous studies reported that this
de novo ceramide synthesis needs a relatively long time
period to use raw materials to synthesize the product,
which indicated that this pathway might not serve as a
signaling mechanism. However, recent studies have re-
ported that ceramide may be synthesized rapidly through
its de novo pathway and, therefore, this de novo synthe-
sized ceramide may also serve as a signaling molecule
to mediate the actions of different stimuli [23, 37, 38].
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It has been reported that de novo ceramide synthesis is
stimulated by many apoptotic and cytotoxic agents, such
as daunorubicin, phorbol ester, and D 609 [24, 39, 40],
as well as some hormones, autocrines, and paracrines,
such as thyroid hormones, angiotensin II, and others [20,
24]. Therefore, the ceramide synthesis through this path-
way as a signaling mechanism may mediate the actions
of these agents or factors. The first step in de novo ce-
ramide synthesis is the condensation of palmitoyl-CoA
with L-serine in a reaction catalyzed by serine palmtrans-
ferase. This is followed by the formation of ceramide
resulting from the N-acylation of dihydrosphingosine or
sphingosine by ceramide synthase, which is inhibited by
the fungal toxin FB1. The inhibition apparently arises
from the remarkable structural similarities between FB1
and sphingoid bases, such as sphinganine and sphingo-
sine, which are substrates for ceramide synthase. In the
present study, we found that FB1 completely abolished L-
Hcys–induced ceramide production, suggesting L-Hcys–
induced ceramide production through de novo ceramide
synthesis in rat MG cells. Taken together, our results in-
dicate that L-Hcys increases the de novo ceramide syn-
thesis in the MG cells, and this lipid-signaling pathway
may mediate the action of L-Hcys–induced activation of
NADH/NADPH oxidase, resulting in O2− production in
these MG cells.
To further test this hypothesis, we explored the
mechanism by which L-Hcys or ceramide activates
NADH/NADPH oxidase. In the first series of exper-
iments, we determined whether L-Hcys or ceramide
increases the activity of this enzyme by stimulating
translocation of its p47phox subunit from cytosol to the
plasma membrane in rat MG cells. We concentrated on
membrane translocation of these NADH/NADPH oxi-
dase subunits because its translocation is considered to be
an important mechanism in mediating NADH/NADPH
activation in a variety of cells, including macrophages,
vascular smooth muscle, and endothelial cells [18, 26,
41]. Due to the fact that p67phox together with p47phox
translocates from cytosol to membrane for the function
of NADH/NADPH oxidase, we also detected the abun-
dance of p67phox in membrane and cytosol. By West-
ern blot analysis, we found that the subunit p47phox and
p67phox were detectable in the cell membrane in rat MG
cells under basic culture condition without stimulation
of L-Hcys or ceramide, and the abundance of p47phox
NADH/NADPH oxidase subunit in this fraction at levels
was even higher than its cytosolic counterpart. Neither
L-Hcys nor ceramide changed the abundance of p47phox
and p67phox in the cell membrane or cytosol. This indicates
translocation of p47phox and p67phox seems not to be in-
volved in L-Hcys–induced activation of NADH/NADPH
oxidase in rat MG cells.
Next, we determined whether another important
mechanism activating NADH/NADPH oxidase con-
tributes to the action of L-Hcys and ceramide, which
is Rac GTPase-mediated activation. Recently, rapid
progress has been made in unraveling the involvement
of this small GTP-binding protein in regulating the
NADH/NADPH oxidase activity [42–44]. Rac is a mem-
ber of the Rho family of GTP-binding proteins, and it is
regulated by binding GTP for activation and hydrolyz-
ing GTP to GDP for inactivation. Thus, the Rac “ac-
tivity” has been generally viewed as being synonymous
with GTP binding. In previous studies, the role of Rac
as a regulator of NADH/NADPH oxidase complex was
described in phagocytes [45]. Recently, this Rac activa-
tion of NADH/NADPH oxidase has also been reported
in nonphagocytic cells, such as vascular smooth mus-
cle and endothelial cells. In the present study, a specific
GTP-bound protein pull-down assay was used to detect
activated Rac, and therefore, determined whether Rac
GTPase can be activated by L-Hcys or ceramide in rat
MG cells. It was found that both Hcys and ceramide sig-
nificantly increased activated Rac abundance, but they
had no effects on total Rac levels in rat MG cells. It is
clear that Rac activity is involved in the action of L-Hcys
or ceramide on NADH/NADPH oxidase activity.
Despite observations that both L-Hcys and ceramide
produced a similar action increasing activated Rac in rat
MG cells, it remains unclear at this point whether L-
Hcys–induced Rac activation is associated with enhanced
de novo ceramide synthesis. Therefore, we examined the
effect of inhibition of de novo ceramide synthesis on L-
Hcys–induced increase in activated Rac in these MG cells.
The results demonstrated that the inhibitor of de novo ce-
ramide synthesis, FB1, completely blocked the action of
L-Hcys on Rac activity, and that in the presence of FB1,
activated Rac was even lower than the basal levels. These
results suggest that the de novo synthesized ceramide not
only participates in the action of Hcys, but also plays a role
in maintaining basal activity of Rac in rat MG cells. It is
obvious that ceramide signaling is of importance in the
regulation of Rac activity.
While the present study did not attempt to address how
ceramide activates Rac or increases GTP binding to Rac,
recent studies have reported that ceramide may stimu-
late Vav [46–49], a member of Ras GTP-binding protein
superfamily through a protein tyrosine kinase (PTK)-
independent alternative pathway, and thereby activates
a guanine nucleotide exchange factor (GEF) specific to
Rac. This GEF accelerates GDP exchange by GTP or Rac
activation by catalyzing the release of the bound GDP.
Further studies will be performed in a separate future
study to address whether L-Hcys or ceramide alters Vav
activity, and thereby activates GEF.
In the present study, we also determined whether L-
Hcys–induced de novo ceramide synthesis, and Rac acti-
vation really enhances NADH/NADPH oxidase activity
and O2− production. Using fluorescence spectrometric
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Fig. 10. Proposed mechanism by which Hcys
activates NADH/NADPH oxidase. First, L-
Hcys stimulated the de novo ceramide syn-
thesis. Next, increased ceramide activated
Rac GTPase via the activation of GEF
(study in progress), and thereby increased
NADH/NADPH oxidase activity. Abbrevi-
ations: GEF, guanine nucleotide exchange
factor; GAP, GTPase activiating protein;
GTP, guanosine triphosphate; GDP, guano-
sine diphosphate; Pi, inorganic phosphate.
assay, the formation rate of ethidium from dihydroethi-
dine in the homogenates of rat MG cells specific to
NADH incubation was determined to represent NADH/
NADPH oxidase activity. As reported previously [6], L-
Hcys was found to significantly increase NADH/NADPH
oxidase activity. In the presence of Rac inhibitor, GDPbS,
L-Hcys–induced increase in NADH/NADPH activity
was completely blocked, suggesting that Hcys-induced
activation is associated with Rac activity. In addition, de
novo ceramide synthesis inhibitor, FB1, also blocked L-
Hcys–induced increase in NADH/NADPH oxidase ac-
tivity. These findings together confirmed that Hcys stim-
ulated NADH/NADPH oxidase through activation of
ceramide-Rac signaling pathway in MG cells. The de novo
ceramide synthesis is importantly involved in L-Hcys–
induced activation of Rac GTPase.
CONCLUSION
The present study demondtrated that a lipid-signaling
molecule, ceramide, increased through its de novo syn-
thesis activation by L-Hcys in rat MG cells, and that
ceramide activated Rac GTPase, and thereby enhanced
NADH/NADPH oxidase activity. As shown in Figure 10,
it has been concluded that L-Hcys activates ceramide syn-
thase to enhance de novo ceramide synthesis. Increased
ceramide stimulates Rac activity by enhancing exchange
of GDP and GTP through GEF, and thereby leads to
NADPH oxidase activiation, producing superoxide us-
ing NADPH or NDAH as substrate. This represents a
new pathway mediating Hcys-induced glomerular injury.
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